Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05672966
Other study ID # BV-C601-202201
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date August 1, 2023
Est. completion date October 31, 2024

Study information

Verified date December 2022
Source Wuhan BravoVax Co., Ltd.
Contact Long Xu, Ph.D.
Phone +86 27 8798 8585 ext. 8251
Email ct@bravovax.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date October 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Men and women aged between 18 and 35 years (inclusive) at the time of Screening Visit. - In good general health, with no significant medical history, and have no clinically significant abnormalities on vital signs, physical examination, laboratory tests, and ECG at Screening Visit and before the first vaccination of IP at the discretion of the Investigator(s) or designee. - Body Mass Index (BMI) of = 18.0 and = 32.0 (BMI will be calculated by weight in kilograms [kg]/square of height in meters [m2]) and weigh at least 50 kg at Screening Visit. - Able and willing to comply with all study requirements and study procedures. - Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures. - Male and female of childbearing age should agree to take effective contraception measures Exclusion Criteria: - Physical or psychological medical histories (within 3 months prior to Screening Visit) or ongoing conditions of any clinically significant hepatic (eg, active liver disease, hepatic impairment), renal/genitourinary (eg, renal impairment), gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological, hematological disease, and/or any other medical conditions which, at the discretion of the Investigator(s), may jeopardize the safety of the participants and/or effect the results of the study. - Histories or on-going conditions of immune function impaired, congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases. - Histories or on-going conditions of malignancy, except for non-melanoma skin cancer, excised more than 2 years ago. - History of abnormal cervical biopsy results (showing cervical intraepithelial neoplasia or worse) or cervical disease (ie, surgical treatment for cervical lesions) within 5 years prior to Screening Visit. - History of a positive test for HPV infection. - Histories of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents. - Loss of spleen or functional spleen, and/or removal of spleen caused by any situation - Body temperature before vaccination = 38? for ear or temporal artery temperature or = 37.2 ? for armpit temperature before vaccination. - Systolic blood pressure = 140 mmHg and/or a diastolic blood pressure = 90 mmHg before vaccination. - Receipt of systemic immunosuppressants or immune-modifying drugs for > 14 days in total within 6 months prior to Screening Visit (for corticosteroids = 20 mg/day of prednisone equivalent). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. - Receipt of immunoglobulins and/or any blood products within the 3 months prior to the first vaccination or planned administration during the study period. - Receipt of any HPV vaccination within 3 months prior to the first vaccination. Receipt of any vaccination other than HPV vaccination within 30 days prior to first vaccination. Plan to receive any vaccination within 7 days prior to the secondary or third IP vaccination. Plan to receive any vaccination within 30 days after the first, secondary, or third IP vaccination. - Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first vaccination of IP. - Use of (or anticipated use of) any prescription drugs (other than hormonal contraception; oral contraceptive pills [OCPs], long-acting implantable hormones, injectable hormones, a vaginal ring, or an IUD), over the counter (OTC) medication, or herbal remedies 2 weeks prior to dosing and during course of study, unless the medication will not affect the safety and efficacy evaluations in the study at the discretion of the Investigator(s). - Regular alcohol consumption defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit or a 125 mL glass of wine). - Positive toxicology panel (urine test including qualitative identification of barbiturates, THC, amphetamines, benzodiazepines, opiates, and cocaine). - Positive results of hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), HIV antibody, HPV, SARS-CoV-2, and pregnancy test. - Pregnancy or breast feeding or plan to get pregnant or breastfeed during the study. - Anything that the Investigator(s) considers that may jeopardise the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.

Study Design


Intervention

Biological:
Human papillomavirus (HPV) Vaccine
0.5mL, Intramuscular
Placebo
0.5mL, Intramuscular

Locations

Country Name City State
Australia Paratus Clinical Research Canberra Canberra

Sponsors (3)

Lead Sponsor Collaborator
Wuhan BravoVax Co., Ltd. Novotech (Australia) Pty Limited, Shanghai BravoBio Co., Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety in terms of solicited adverse events Occurrence of solicited AEs of each subject within 7 days after each vaccination
Primary Safety in terms of solicited systemic AEs Occurrence of solicited systemic AEs of each subject within 7 days after the first vaccination
Primary Safety in terms of dose-limiting toxicity (DLT) Percentage of participants with dose-limiting toxicity within 30 days after the first vaccination
Primary Safety in terms of unsolicited AEs Percentage of participants with unsolicited AEs 365 days after the first vaccination
Primary Safety in terms of all solicited and unsolicited AEs Frequency and severity of solicited and unsolicited AEs 365 days after the first vaccination
Secondary Immunogencity in terms of GMT by ELISA GMT of anti-L2 immunoglobulin G (IgG) antibody responses Days 1, 31, 61, 91, 121, 181, 211, and 365
Secondary Immunogencity in terms of Nab GMT of anti-HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73 type specific serum neutralizing antibody (NAb) response Days 1, 31, 61, 91, 121, 181, 211, and 365
Secondary Immunogencity in terms of Seroconversion rate Seroconversion rate of anti-L2 IgG antibody and anti-HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73 type-specific serum Nab Days 1, 31, 61, 91, 121, 181, 211, and 365
See also
  Status Clinical Trial Phase
Completed NCT05458869 - Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
Completed NCT01932697 - Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer Phase 2
Completed NCT03265743 - HPV Vaccination in Women With Cystic Fibrosis N/A
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A
Completed NCT06199128 - Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
Active, not recruiting NCT01824537 - Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Phase 4
Completed NCT01265212 - Prevalence of Human Papillomavirus in Men Living in the Northern Plains N/A
Unknown status NCT01087164 - Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers N/A
Terminated NCT01082861 - Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination Phase 4
Completed NCT00572832 - Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting N/A
Completed NCT03158220 - Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Phase 3
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Completed NCT05680454 - A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine Phase 1
Completed NCT04133610 - HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs N/A
Completed NCT00988884 - A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) Phase 3
Not yet recruiting NCT05981807 - HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
Recruiting NCT03302858 - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Phase 2
Completed NCT01694875 - Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System N/A
Completed NCT01205412 - An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain N/A